J Krzystyniak1, L Ceppi1, D S Dizon2, M J Birrer3. 1. Center for Cancer Research, Massachusetts General Hospital, Boston. 2. Division of Gynecologic Oncology, Massachusetts General Hospital Cancer Center, Boston Department of Medicine, Harvard Medical School, Boston, USA. 3. Center for Cancer Research, Massachusetts General Hospital, Boston Division of Gynecologic Oncology, Massachusetts General Hospital Cancer Center, Boston Department of Medicine, Harvard Medical School, Boston, USA mbirrer@partners.org.
Abstract
BACKGROUND: Epithelial ovarian cancer (EOC) remains one of the leading causes of cancer-related deaths among women worldwide, despite gains in diagnostics and treatments made over the last three decades. Existing markers of ovarian cancer possess very limited clinical relevance highlighting the emerging need for identification of novel prognostic biomarkers as well as better predictive factors that might allow the stratification of patients who could benefit from a more targeted approach. PATIENTS AND METHODS: A summary of molecular genetics of EOC. RESULTS: Large-scale high-throughput genomic technologies appear to be powerful tools for investigations into the genetic abnormalities in ovarian tumors, including studies on dysregulated genes and aberrantly activated signaling pathways. Such technologies can complement well-established clinical histopathology analysis and tumor grading and will hope to result in better, more tailored treatments in the future. Genomic signatures obtained by gene expression profiling of EOC may be able to predict survival outcomes and other important clinical outcomes, such as the success of surgical treatment. Finally, genomic analyses may allow for the identification of novel predictive biomarkers for purposes of treatment planning. These data combined suggest a pathway to progress in the treatment of advanced ovarian cancer and the promise of fulfilling the objective of providing personalized medicine to women with ovarian cancer. CONCLUSIONS: The understanding of basic molecular events in the tumorigenesis and chemoresistance of EOC together with discovery of potential biomarkers may be greatly enhanced through large-scale genomic studies. In order to maximize the impact of these technologies, however, extensive validation studies are required.
BACKGROUND:Epithelial ovarian cancer (EOC) remains one of the leading causes of cancer-related deaths among women worldwide, despite gains in diagnostics and treatments made over the last three decades. Existing markers of ovarian cancer possess very limited clinical relevance highlighting the emerging need for identification of novel prognostic biomarkers as well as better predictive factors that might allow the stratification of patients who could benefit from a more targeted approach. PATIENTS AND METHODS: A summary of molecular genetics of EOC. RESULTS: Large-scale high-throughput genomic technologies appear to be powerful tools for investigations into the genetic abnormalities in ovarian tumors, including studies on dysregulated genes and aberrantly activated signaling pathways. Such technologies can complement well-established clinical histopathology analysis and tumor grading and will hope to result in better, more tailored treatments in the future. Genomic signatures obtained by gene expression profiling of EOC may be able to predict survival outcomes and other important clinical outcomes, such as the success of surgical treatment. Finally, genomic analyses may allow for the identification of novel predictive biomarkers for purposes of treatment planning. These data combined suggest a pathway to progress in the treatment of advanced ovarian cancer and the promise of fulfilling the objective of providing personalized medicine to women with ovarian cancer. CONCLUSIONS: The understanding of basic molecular events in the tumorigenesis and chemoresistance of EOC together with discovery of potential biomarkers may be greatly enhanced through large-scale genomic studies. In order to maximize the impact of these technologies, however, extensive validation studies are required.
Authors: Dimitrios Spentzos; Douglas A Levine; Marco F Ramoni; Marie Joseph; Xuesong Gu; Jeff Boyd; Towia A Libermann; Stephen A Cannistra Journal: J Clin Oncol Date: 2004-10-25 Impact factor: 44.544
Authors: K Obata; S J Morland; R H Watson; A Hitchcock; G Chenevix-Trench; E J Thomas; I G Campbell Journal: Cancer Res Date: 1998-05-15 Impact factor: 12.701
Authors: David M Gershenson; Charlotte C Sun; Karen H Lu; Robert L Coleman; Anil K Sood; Anais Malpica; Michael T Deavers; Elvio G Silva; Diane C Bodurka Journal: Obstet Gynecol Date: 2006-08 Impact factor: 7.661
Authors: Tomas Bonome; Ji-Young Lee; Dong-Choon Park; Mike Radonovich; Cindy Pise-Masison; John Brady; Ginger J Gardner; Ke Hao; Wing H Wong; J Carl Barrett; Karen H Lu; Anil K Sood; David M Gershenson; Samuel C Mok; Michael J Birrer Journal: Cancer Res Date: 2005-11-15 Impact factor: 12.701
Authors: Kristin K Zorn; Tomas Bonome; Lisa Gangi; Gadisetti V R Chandramouli; Christopher S Awtrey; Ginger J Gardner; J Carl Barrett; Jeff Boyd; Michael J Birrer Journal: Clin Cancer Res Date: 2005-09-15 Impact factor: 12.531
Authors: Ivo Meinhold-Heerlein; Dirk Bauerschlag; Felix Hilpert; Petre Dimitrov; Lisa M Sapinoso; Marzenna Orlowska-Volk; Thomas Bauknecht; Tjoung-Won Park; Walter Jonat; Anja Jacobsen; Jalid Sehouli; Jutta Luttges; Maryla Krajewski; Stan Krajewski; John C Reed; Norbert Arnold; Garret M Hampton Journal: Oncogene Date: 2005-02-03 Impact factor: 9.867
Authors: Toni M Robinson-Smith; Idit Isaacsohn; Carol A Mercer; Mingfu Zhou; Nico Van Rooijen; Nader Husseinzadeh; Molly M McFarland-Mancini; Angela F Drew Journal: Cancer Res Date: 2007-06-15 Impact factor: 12.701
Authors: Kathleen M Schmeler; Charlotte C Sun; Diane C Bodurka; Michael T Deavers; Anais Malpica; Robert L Coleman; Pedro T Ramirez; David M Gershenson Journal: Gynecol Oncol Date: 2007-12-26 Impact factor: 5.482
Authors: Rachel N Grisham; Brooke E Sylvester; Helen Won; Gregory McDermott; Deborah DeLair; Ricardo Ramirez; Zhan Yao; Ronglai Shen; Fanny Dao; Faina Bogomolniy; Vicky Makker; Evis Sala; Tara E Soumerai; David M Hyman; Nicholas D Socci; Agnes Viale; David M Gershenson; John Farley; Douglas A Levine; Neal Rosen; Michael F Berger; David R Spriggs; Carol A Aghajanian; David B Solit; Gopa Iyer Journal: J Clin Oncol Date: 2015-08-31 Impact factor: 44.544
Authors: Michael J Birrer; Michael E Johnson; Ke Hao; Kwong-Kwok Wong; Dong-Choon Park; Aaron Bell; William R Welch; Ross S Berkowitz; Samuel C Mok Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544